In the U.S., in May 2025, an executive order was issued directing federal agencies to pursue actions intended to reduce prescription drug prices charged in other developed countries, including by directing the Department of Health and Human Services (HHS) to establish a most-favored-nation (MFN) price target applicable to Medicare and Medicaid programs. To date, we have not been contacted by federal officials regarding the pricing of any of our products, and it is not clear whether our products are within scope of this executive order.
All entries for: Indivior
August 28, 2025
Indivior
Layoffs
North Chesterfield, VA
1,001-5,000 employees
Indivior is letting go of an undisclosed number of employees as it sets in motion its “Indivior Action Agenda,” a sweeping and multi-year strategic initiative to “maximize the potential” of its business. The layoffs are expected to cost Indivior some $16 million to $19 million in one-time severance payments. Aside from the workforce reduction, Indivior will also consolidate and reduce its real estate assets, for which it expects to incur $15 million to $22 million in one-time costs. The company is also looking for “strategic alternatives” for its opioid use disorder therapy Opvee, though it did not specify what options it is currently exploring.
Disease Area: Chronic Disease, Psychiatry
Drug Type: Small Molecule